Essex Bio-Technology (SEHK:1061) - Cotización, noticias y análisis

Resumen de acción 1061

Essex Bio-Technology Limited, un holding de inversiones, desarrolla, fabrica, distribuye y vende productos biofarmacéuticos en la República Popular China, Hong Kong e internacionalmente.

Acerca de la empresa

1061 análisis fundamental
Puntuación del copo de nieve
Valoración	2/6
Crecimiento futuro	0/6
Resultados anteriores	4/6
Salud financiera	6/6
Dividendos	4/6

Recompensas

El ratio precio-beneficios (4.5x) es inferior al del mercado Hong Kong (9.1x)

Los beneficios aumentaron un 22.1% el pasado año

Análisis de riesgos

Historial de dividendos inestable

Competidores de Essex Bio-Technology Limited

Uni-Bio Science Group

SEHK:690

HK$332.8m

HBM Holdings

SEHK:2142

HK$996.5m

3SBio

SEHK:1530

HK$15.9b

Shanghai Haohai Biological Technology

SEHK:6826

HK$13.9b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Essex Bio-Technology
Precios históricos de las acciones
Precio actual de la acción	HK$2.48
Máximo en 52 semanas	HK$3.49
Mínimo de 52 semanas	HK$1.96
Beta	0.25
11 mes Cambio	-2.75%
Variación en 3 meses	12.73%
Cambio de 1 año	-28.32%
3Variación en 3 años	-67.15%
Variación en 5 años	-64.57%
Variación desde la OPV	150.51%

Noticias y actualizaciones recientes

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

May 06

Recent updates

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

May 02

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Mar 30

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Jun 29

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Mar 31

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Mar 13

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Jan 25

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 04

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 13

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Nov 23

Rentabilidad de los accionistas

	1061	HK Biotechs	Mercado HK
7D	6.0%	0.5%	-2.4%
1Y	-28.3%	-34.5%	0.6%

Rentabilidad vs. Industria: 1061 superó a la industria Hong Kong Biotechs, que obtuvo un rendimiento del -34.6% el año pasado.

Rentabilidad vs. Mercado: 1061 obtuvo unos resultados inferiores a los del mercado Hong Kong, que fue del -10.1% el año pasado.

Volatilidad de los precios

Is 1061's price volatile compared to industry and market?
1061 volatility
1061 Average Weekly Movement	4.7%
Biotechs Industry Average Movement	8.6%
Market Average Movement	6.9%
10% most volatile stocks in HK Market	14.8%
10% least volatile stocks in HK Market	3.7%

Precio estable de las acciones: 1061 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 1061 (6%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1990	1,481	Haizhou Fang	www.essexbio.com

Essex Bio-Technology Limited, un holding de inversiones, desarrolla, fabrica, distribuye y vende productos biofarmacéuticos en la República Popular China, Hong Kong e internacionalmente. La empresa opera a través de los segmentos de Oftalmología y Cirugía. Investiga y desarrolla productos terapéuticos de factor de crecimiento de fibroblastos para el tratamiento de la proliferación, diferenciación y migración celular.

Resumen de fundamentos de Essex Bio-Technology Limited

¿Cómo se comparan los beneficios e ingresos de Essex Bio-Technology con su capitalización de mercado?
Estadísticas fundamentales de 1061
Capitalización bursátil	HK$1.41b
Beneficios(TTM)	HK$275.26m
Ingresos (TTM)	HK$1.71b

5.1x

Ratio precio-beneficio (PE)

0.8x

Ratio precio-ventas (PS)

¿Está 1061 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 1061
Ingresos	HK$1.71b
Coste de los ingresos	HK$167.26m
Beneficio bruto	HK$1.54b
Otros gastos	HK$1.26b
Beneficios	HK$275.26m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	0.49
Margen bruto	90.20%
Margen de beneficio neto	16.13%
Ratio deuda/patrimonio	14.1%

¿Cómo se ha desempeñado 1061 a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

3.6%

Rentabilidad actual por dividendo

19%

Ratio de pagos

Resumen de acción 1061

Recompensas

Análisis de riesgos

Competidores de Essex Bio-Technology Limited

SEHK:690

HK$332.8m

SEHK:2142

HK$996.5m

SEHK:1530

HK$15.9b

SEHK:6826

HK$13.9b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.045 per share

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Now 21% overvalued

Now 22% overvalued

Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024

Recent updates

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.045 per share

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Now 21% overvalued

Now 22% overvalued

Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024

Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Essex Bio-Technology Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Financial data availability

Essex Bio-Technology Limited to Report Fiscal Year 2023 Results on Mar 18, 2024

Investor sentiment deteriorates as stock falls 16%

Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Upcoming dividend of HK$0.045 per share at 2.0% yield

First half 2023 earnings released: EPS: HK$0.30 (vs HK$0.24 in 1H 2022)

Essex Bio-Technology Limited to Report First Half, 2023 Results on Aug 16, 2023

Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative (Wet) Age-Related Macular Degeneration

Less than half of directors are independent

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.025 per share at 1.8% yield

Now 21% undervalued after recent price drop

Essex Bio-Technology Limited Completes First Patient First Dose in the United States in an International Multi-Centre Phase 3 Clinical Study

Essex Bio-Technology Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Price target decreased to HK$6.00

Less than half of directors are independent

Consensus revenue estimates fall by 18%

Upcoming dividend of HK$0.04 per share

Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

First half 2022 earnings released: EPS: HK$0.24 (vs HK$0.28 in 1H 2021)

Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on September 21, 2022

Essex Bio-Technology Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021

Price target increased to HK$7.00

Less than half of directors are independent

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.04 per share

First half 2021 earnings released: EPS HK$0.28 (vs HK$0.085 in 1H 2020)

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021 at the Annual General Meeting held on May 12, 2021

Upcoming dividend of HK$0.05 per share

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Essex Bio-Technology Limited Announces Dividend for the Year Ended December 31, 2020, Payable on 1 June 2021

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Essex Bio-Technology Limited, Annual General Meeting, May 12, 2021

Full year 2020 earnings released: EPS HK$0.38 (vs HK$0.52 in FY 2019)

Essex Bio-Technology Limited to Report Fiscal Year 2020 Results on Mar 12, 2021

Investor sentiment improved over the past week

Essex Bio-Technology Limited Announces Positive Outcome of U.S. FDA Second Phase 3 Clinical Trial in Dry Eye Disease

New 90-day high: HK$4.85

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Investor sentiment improved over the past week